JP2019521986A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521986A5
JP2019521986A5 JP2018565786A JP2018565786A JP2019521986A5 JP 2019521986 A5 JP2019521986 A5 JP 2019521986A5 JP 2018565786 A JP2018565786 A JP 2018565786A JP 2018565786 A JP2018565786 A JP 2018565786A JP 2019521986 A5 JP2019521986 A5 JP 2019521986A5
Authority
JP
Japan
Prior art keywords
chromatography
antibody
mixed mode
anion exchange
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018565786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521986A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038007 external-priority patent/WO2017218977A2/en
Publication of JP2019521986A publication Critical patent/JP2019521986A/ja
Publication of JP2019521986A5 publication Critical patent/JP2019521986A5/ja
Priority to JP2022117433A priority Critical patent/JP7564843B2/ja
Priority to JP2024102664A priority patent/JP2024156655A/ja
Pending legal-status Critical Current

Links

JP2018565786A 2016-06-17 2017-06-16 多重特異性抗体の精製 Pending JP2019521986A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022117433A JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製
JP2024102664A JP2024156655A (ja) 2016-06-17 2024-06-26 多重特異性抗体の精製

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351908P 2016-06-17 2016-06-17
US62/351,908 2016-06-17
PCT/US2017/038007 WO2017218977A2 (en) 2016-06-17 2017-06-16 Purification of multispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022117433A Division JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製

Publications (2)

Publication Number Publication Date
JP2019521986A JP2019521986A (ja) 2019-08-08
JP2019521986A5 true JP2019521986A5 (enExample) 2020-08-06

Family

ID=59593150

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018565786A Pending JP2019521986A (ja) 2016-06-17 2017-06-16 多重特異性抗体の精製
JP2022117433A Active JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製
JP2024102664A Pending JP2024156655A (ja) 2016-06-17 2024-06-26 多重特異性抗体の精製

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022117433A Active JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製
JP2024102664A Pending JP2024156655A (ja) 2016-06-17 2024-06-26 多重特異性抗体の精製

Country Status (18)

Country Link
US (1) US20190256556A1 (enExample)
EP (2) EP3472177B1 (enExample)
JP (3) JP2019521986A (enExample)
KR (3) KR20250107275A (enExample)
CN (1) CN109563124A (enExample)
AR (1) AR108800A1 (enExample)
AU (2) AU2017286676B2 (enExample)
BR (1) BR112018075516A2 (enExample)
CA (1) CA3026518A1 (enExample)
ES (1) ES2988363T3 (enExample)
HR (1) HRP20241323T1 (enExample)
HU (1) HUE068564T2 (enExample)
IL (1) IL263690B2 (enExample)
MX (2) MX2018015173A (enExample)
PL (1) PL3472177T3 (enExample)
SG (1) SG11201810777WA (enExample)
TW (1) TWI798179B (enExample)
WO (1) WO2017218977A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3676280B1 (en) * 2017-08-30 2025-03-19 Fresenius Kabi Deutschland GmbH Method for purifying anti-il-6 receptor antibodies
CN111491951B (zh) * 2017-12-22 2024-05-24 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
WO2019149693A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process and platform
US20210040146A1 (en) * 2018-01-30 2021-02-11 Exothera S.A. Protein purification process
WO2019154776A1 (en) * 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
WO2020160118A1 (en) 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
CN114981286B (zh) * 2019-05-03 2026-02-13 豪夫迈·罗氏有限公司 降低从纯化平台获得的组合物中酶水解活性速率的方法
CN114026108B (zh) * 2019-06-28 2024-09-10 夏尔巴生物技术(苏州)有限公司 无缝连续流层析方法
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220092958A (ko) * 2019-11-07 2022-07-04 암젠 인크 산물-관련 불순물을 제거하기 위한 양이온 교환 크로마토그래피 동안의 고염 세척
EP4061825A1 (en) * 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography
EP4090666A1 (en) * 2020-01-15 2022-11-23 F. Hoffmann-La Roche AG Methods to decrease impurities from recombinant protein manufacturing processes
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
CN115066258A (zh) * 2020-02-28 2022-09-16 上海药明生物技术有限公司 双特异性抗体的纯化
EP4118093A4 (en) * 2020-03-11 2024-04-17 Dr. Reddy's Laboratories Ltd. METHOD FOR PURIFYING A FC FUSION PROTEIN
CN115734969A (zh) * 2020-04-13 2023-03-03 上海药明生物技术有限公司 双特异性抗体的纯化
US20230143066A1 (en) * 2020-04-17 2023-05-11 Ono Pharmaceutical Co., Ltd. Method for removing color from drug substance of protein preparation
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
AU2021265346A1 (en) * 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of affinity chromatography
EP4142905A4 (en) * 2020-05-01 2024-11-13 Kashiv Biosciences, LLC IMPROVED PROCESS FOR PURIFICATION OF PROTEIN
CN114014906B (zh) * 2020-06-24 2024-01-12 夏尔巴生物技术(苏州)有限公司 一种利用阳离子交换层析纯化疏水性蛋白的方法
CA3191328A1 (en) * 2020-09-21 2022-03-24 Genentech, Inc. Purification of multispecific antibodies
CN114539416B (zh) * 2020-11-26 2024-11-08 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
JP2024500747A (ja) * 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ, リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法
ES3040791T3 (en) 2020-12-18 2025-11-05 Richter Gedeon Nyrt Methods for the purification of refolded fc-peptide fusion protein
BR112023018268A2 (pt) * 2021-03-09 2023-10-31 Japan Chem Res Método para produzir uma proteína de fusão
WO2022225060A1 (ja) * 2021-04-23 2022-10-27 協和キリン株式会社 分解物の産生を抑制する方法
TW202241924A (zh) * 2021-04-23 2022-11-01 大陸商和鉑醫藥(上海)有限責任公司 一種雙特異性抗體的純化方法
WO2022272119A2 (en) * 2021-06-25 2022-12-29 The Board Of Trustees Of The University Of Illinois Synthetic toolkit for plant transformation
WO2023068740A1 (ko) * 2021-10-19 2023-04-27 주식회사 알테오젠 Igg fc 도메인을 가지는 융합 단백질의 정제방법
WO2024076990A1 (en) * 2022-10-03 2024-04-11 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
CN117990807B (zh) * 2022-11-07 2024-09-24 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体电荷异质性的检测方法
CN119264256B (zh) * 2023-07-07 2026-01-02 齐鲁制药有限公司 一种单克隆抗体的纯化方法
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025029614A1 (en) * 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
WO2025088516A1 (en) * 2023-10-26 2025-05-01 Pfizer Inc. Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
WO2025155751A1 (en) * 2024-01-17 2025-07-24 Nutcracker Therapeutics, Inc. Improved method for isolating and characterizing proteins

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541A (en) 1837-12-26 Daniel desmond
US7521A (en) 1850-07-22 Improvement in the
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2002245142B2 (en) 2000-12-14 2007-07-05 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CA2552639C (en) * 2004-02-27 2012-05-01 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008048942B4 (de) 2008-09-25 2011-01-13 Siemens Aktiengesellschaft Anordnung mit einer Wellendichtung
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
MX342235B (es) * 2010-11-05 2016-09-21 Hoffmann La Roche Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
PL2635607T3 (pl) * 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
HRP20240230T1 (hr) 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
AU2013315750B9 (en) * 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
MX2016001601A (es) * 2013-08-19 2016-05-02 Hoffmann La Roche Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita.
EP3060578A4 (en) * 2013-10-25 2017-07-05 Medlmmune, LLC Antibody purification
EP3066123A1 (en) * 2013-11-07 2016-09-14 AbbVie Inc. Isolation and purification of antibodies
SI3116891T1 (sl) * 2014-03-10 2020-07-31 Richter Gedeon Nyrt. Čiščenje imunoglobulina z uporabo predčistilnih stopenj
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
CN116327922A (zh) * 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权(第2 号)有限公司 生物医药组合物

Similar Documents

Publication Publication Date Title
KR101921767B1 (ko) 단백질 정제
JP5448825B2 (ja) 非凝集抗体Fcドメインの製造方法
JP6092892B2 (ja) 抗体の精製方法
CN103382215B (zh) 以流通方式从生物药物制剂中去除蛋白质聚集体
EP3067367B1 (en) Method for purifying recombinant protein
CN102791726B (zh) 纯化免疫球蛋白溶液的方法
CN106457070B (zh) 基于IL-15/IL-15Rα的缀合物的纯化方法
US20200291063A1 (en) Method for separation of monomeric polypeptides from aggregated polypeptides
JP2012507557A5 (enExample)
CN102757496B (zh) 一种抗vegf抗体片段的纯化制备方法
CN101213211A (zh) 纯化含Fc区蛋白的方法
CN111491951B (zh) 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
JP2020508968A (ja) プロテインlを用いたタンパク質精製
JP7656002B2 (ja) 2つ以上の抗体を含む組成物の製造
CN118063620A (zh) 双特异性抗体
US9447171B2 (en) Purification process for fragment antibodies
KR102123700B1 (ko) 혼합 방식 크로마토그래피를 이용한 침출된 단백질 a 제거 방법
KR102899514B1 (ko) 분리 방법
WO2021136256A1 (zh) 一种得到高纯度异源抗体的方法
Wan Biopharmaceutical Applications
CN121930365A (zh) 一种双特异性嵌合蛋白及应用
CN116769049A (zh) 一种双功能融合蛋白的纯化方法
Berg Purification of rh-TNF-α by chromatographic methods
HK40032929A (en) Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2025155864A1 (en) Immunoglobulin-binding proteins and methods of use thereof